In successful clinical trials of drugs for inflammatory bowel disease (IBD), patients who received a placebo were at significantly higher risk for potential harms, according to two systematic reviews.

Abivax to Present Data on Obefazimod at Digestive Disease Week®Presentations Highlight Comprehensive Efficacy, Safety, and Patient-Reported ...

Symptoms of inflammatory bowel disease (IBD) range from diarrhea and abdominal pain to nausea, fever, loss of appetite, fatigue and, at times, rectal bleeding. No single test can confirm IBD, which ...

Poster Presentation at the 2026 Crohn's & Colitis Congress® Showcases Use of Causal Machine Learning and IBD Plexus® to Optimize Trial Execution BOSTON, Jan. 22, 2026 /PRNewswire/ -- PhaseV, a leader ...

Notable news about inflammatory bowel disease (IBD) in 2024 included a study evaluating loss of response to tumor necrosis factor (TNF) blockers, new FDA approvals, problems with placebos, and ...

The MarketWatch News Department was not involved in the creation of this content. Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's ...

(BPT) – Living with inflammatory bowel disease (IBD), such as Crohn’s disease and ulcerative colitis (UC), can be extremely frustrating to people living with the conditions and significantly affect ...

Celltrion, Inc. today announced that seven abstracts will be presented at the 2026 Digestive Disease Week® (DDW) Annual Meeting, taking place May 2-5 in Chicago, Illinois. The oral and poster ...

New research reveals a lack of consensus in defining moderate Crohn’s disease and ulcerative colitis, limiting optimal ...

Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn’s disease, and late-stage clinical trial design Appointments strengthen ...

The oral Janus kinase inhibitor upadacitinib was well tolerated for moderate to severe inflammatory bowel disease over a ...